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Abstract: One of the crucial aspects of screening antisense oligonucleotides destined for therapeutic
application is confidence that the antisense oligomer is delivered efficiently into cultured cells.
Efficient delivery is particularly vital for antisense phosphorodiamidate morpholino oligomers, which
have a neutral backbone, and are known to show poor gymnotic uptake. Here, we report several
methods to deliver these oligomers into cultured cells. Although 4D-Nucleofector™ or Neon™
electroporation systems provide efficient delivery and use lower amounts of phosphorodiamidate
morpholino oligomer, both systems are costly. We show that some readily available transfection
reagents can be used to deliver phosphorodiamidate morpholino oligomers as efficiently as the
electroporation systems. Among the transfection reagents tested, we recommend Lipofectamine
3000™ for delivering phosphorodiamidate morpholino oligomers into fibroblasts and Lipofectamine
3000™ or Lipofectamine 2000™ for myoblasts/myotubes. We also provide optimal programs for
nucleofection into various cell lines using the P3 Primary Cell 4D-Nucleofector™ X Kit (Lonza), as
well as antisense oligomers that redirect expression of ubiquitously expressed genes that may be used
as positive treatments for human and murine cell transfections.
Keywords: antisense oligonucleotide; morpholino; PMO; transfection; electroporation; exon skipping
1. Introduction
Antisense oligonucleotides (ASOs) are short, single-stranded molecules that can be designed to
specifically bind to DNA or RNA via Watson-Crick base pairing, with the aim of modifying specific gene
expression. Although ASOs have been used as laboratory tools since these agents were first reported,
it took more than three decades for their arrival in the clinic as therapeutics. An extensive amount of
time and effort can often be spent on in vitro development, assessment, and validation of antisense
oligomer efficacy, to ensure that the optimal ASOs progress to clinical trials. In 1978, Zamecnik and
Stephenson were the first to report blocking Rous sarcoma viral replication in chick embryo fibroblast
cell cultures after transfection with a 13-nucleotide oligomer and, despite not knowing the mode of
action, proposed the use of ASOs as antiviral agents [1,2]. As natural DNA oligonucleotides with the
phosphodiester backbone are susceptible to enzymatic degradation, chemical modifications to bases
and backbones were developed to enhance binding affinity, increase resistance to nuclease digestion
and allow different modes of action that include specific degradation through RNase H induction or
siRNA action, blocking protein translation or redirecting pre-mRNA processing [3–6]. Since these
modifications and mechanisms were introduced, research into ASO compounds as therapeutics for
many diseases, including those caused by genetic mutations, has grown immensely.
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The U.S. Food and Drug Administration has now approved several ASO drugs involving various
chemistries in different stages of clinical development [7–10]. The success of all approved therapeutic
ASOs was based upon careful design and screening of the optimal sequences, first in an in vitro system
and then in vivo. Therefore, it is imperative to have confidence in a consistent and reliable delivery
protocol to ensure cellular or nuclear uptake of the ASOs [11].
Unlike many other synthetic nucleic acid analogues in clinical development, phosphorodiamidate
morpholino oligomers (PMOs) have a neutral charge and delivering these compounds into cultured
cells can be problematic [5,12,13]. Although gymnotic delivery for some PMOs has been reported in
human myotube cultures when applied at high concentrations [14], this process is largely inefficient.
The inefficiency is generally attributed to the PMO’s inability to translocate through cell membranes
as an uncharged molecule and may be overcome by the addition of a peptide-conjugated tag, which
provides a significant charge to the PMO allowing for easier delivery. Thus, uncharged PMOs generally
require delivery agents or protocols to enhance intracellular uptake, although recently Miyatake et al.
(2019) demonstrated that scavenger Receptor Class A1 mediated uptake of PMOs both in vitro and
in vivo [15]. This study may provide further insight into the gymnotic uptake of these compounds and
lead towards an improved drug delivery system.
One must be confident that any transfection protocol used efficiently delivers the PMO into the
cell. As learnt from previous reports, in vitro analysis of DMD exon 46 skipping using a morpholino
oligomer was ineffective compared to the same sequence composed of 2′O-methyl-modified bases
on a phosphorothioate backbone (2′-OMe ASOs) [16]. Conversely, in vivo assessment of PMOs
showed efficient exon 46 skipping of the DMD transcript in humanised DMD mice [17]. Therefore,
the discrepancy between these results arose from an issue of delivery rather than an ineffective ASO,
highlighting the need for confidence in efficient delivery in vitro during ASO development.
The importance of PMO chemistry for protein studies was revealed during the development of
ASOs to correct the defect in the canine model of DMD [18]. Antisense oligomer optimisation to skip
dystrophin exons 6 and 8 used the 2′-OMe ASOs, and while this chemistry was suitable for RNA
studies, detecting dystrophin restoration was not possible [18]. However, when the equivalent ASOs
were prepared as PMOs or PMOs conjugated to a peptide-conjugated tag (PPMO), dystrophin protein
of near full-length was readily detected [18]. When the uncomplexed PMO cocktail was added to cell
media, uptake was poor and dystrophin expression modest. In contrast, the PPMO-treated canine
DMD cells showed robust multi-exon skipping and unequivocal dystrophin restoration [18].
One simple and relatively effective means of delivering PMOs into cultured cells is
“scrape-loading”, where adherent cells are gently scraped to create small transient holes in the
plasma membrane, thus allowing for better uptake of the PMO [19]. Alternatively, Gebski et al.
reported annealing sense-strand DNA “leashes” to antisense PMOs, thereby allowing the negatively
charged PMO: DNA duplex to form complexes with commercially available cationic lipid transfection
reagents [20]. In this approach, the PMO delivery is more comparable to that used to transfect the
commonly used ASOs composed of 2′-OMe or locked nucleic acid (LNA) oligomers. Gene Tools has
developed a novel peptide-mediated delivery reagent, Endo-Porter, that allows PMO delivery via
endocytosis to adhered cells without the use of a leash [21]. Electroporation-mediated transfection
using a 4D-Nucleofector™ or Neon™ system also offers efficient delivery of PMOs to different cell
types, including both adherent and suspension cells [22,23].
The first compound to be granted accelerated approval for the treatment of Duchenne muscular
dystrophy, Exondys 51, was developed in our laboratory [24–26], and we are currently researching
nucleic acid therapeutics for numerous diseases amendable to RNA splicing intervention [24,25,27–29].
Consequently, we have experience in the design, delivery and evaluation of hundreds of PMOs in
different cell lines to address various mutations. We found that PMOs can be delivered into adherent
cells, without a leash, using commercially available cationic lipid-mediated transfection reagents, with
an efficiency similar to that observed with nucleofection. Cationic lipid transfection reagents were
chosen due to the ease of accessibility to most laboratories throughout the world. In addition, little
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literature exists regarding alternative transfection methods. Of the transfection reagents evaluated, we
found that Lipofectamine 3000™ had the least impact on cell morphology and viability but offered
relatively effective PMO delivery into fibroblasts. In addition to Lipofectamine 3000™, Lipofectamine
2000™ also offered effective PMO delivery into cultured myoblasts/myotubes. Nucleofector or Neon
electroporator instruments and their consumables are relatively costly; however, the advantage of these
delivery systems is that the PMO can be delivered to as many as 20 or 6 million cells, respectively, using
substantially lower amounts of PMO. Consequently, we routinely use nucleofection for PMO delivery,
and we report optimised PMO delivery programs using the P3 Primary Cell 4D-Nucleofector™ X Kit
(Lonza) that can be used for various cell lines.
2. Results
2.1. PMO Delivery into Human Dermal Fibroblasts
We have chosen previously optimised exon skipping PMOs targeting the ITGA4 and SMN
transcripts expressed in most cell types and cell lines (Figure S1). To determine whether the nominated
widely used cationic lipid transfection reagents available in the laboratory offer an economical and
reliable method to deliver PMOs into human dermal fibroblasts, we selected two commonly used
cationic lipid transfection reagents; Lipofectamine 3000™ and Lipofectin™, for complex formation with
ASO 1, optimised to induce skipping of exons 3 and 4 from the ITGA4 pre mRNA transcript [30]. In
addition to the lipoplex: PMO transfection, alternative transfection strategies including nucleofection,
Endo-Porter and gymnotic uptake of uncomplexed PMO were evaluated in a direct comparison. The
same experiments were repeated using human myoblasts, except Lipofectin™ was replaced with
Lipofectamine 2000™ for comparison, as the latter shows better transfection efficiency in myoblasts in
our laboratory.
The morphology and viability of fibroblasts and myoblasts treated with PMOs complexed with
the Lipofectamine 3000™ reagent were similar to that of cells treated with the uncomplexed PMO and
untreated fibroblasts or myoblasts (Figure 1A,B). In contrast, substantial cell death was observed after
fibroblasts were treated with PMO complexed with Lipofectin™ (10 µl/mL) and myoblasts treated
with PMO: Lipofectamine 2000™ complex (Figure 1C,D). Nucleofection did not visibly affect the
morphology or viability of the fibroblasts or myoblasts (Figure 1A–D). The morphology of fibroblast
cultures after Endo-Porter-mediated PMO delivery was atypical when compared to other reagents
(Figure 1A). Aggregates, possibly complexes of PMO and peptide, bordered the cells, and small cell
bodies with slender cell extensions were prominent in Endo-porter treated cells, but not observed in
untreated fibroblasts.
The uptake of ASO 1 and subsequent ability to redirect pre-mRNA processing was demonstrated
by RT-PCR analysis of the ITGA4 transcripts (Figure 1E,F). All treatments, except for the uncomplexed
PMO, induced exon 3 and 4 skipping with similar efficiencies, although higher levels of exon skipping
were observed in the fibroblasts treated with PMO: Lipofectin. Increased levels of exon skipping
may have been a consequence of the extensive cell death observed after the Lipofectin™ transfection,
compared to the other treatments. Similarly, myoblasts treated with PMO: Lipofectamine 2000™
caused more than 50% cell death. The average percentages of exon skipping from three biological
replicates are shown in Figure 1E,F and the original gel images are shown in Supplementary Figure S3.
Although evidence of cell death appeared minimal after Endo-Porter-mediated PMO delivery
(Figure 1C,D), the fibroblasts nevertheless showed signs of cell stress. Therefore, we analysed the
expression profile of the cell stress-related proteins using the proteome profiler human cell stress
array kit (Figure S2), which consists of an analysis of relative expression levels of 26 cell stress-related
proteins. Although the levels of some of the stress-related proteins were altered, the most compelling
changes were observed in two proteins, Cited 2 and p21, which were decreased by more than 50% in
Endo-Porter treated fibroblasts, compared to the untreated cells.
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Figure 1. Micrographs of fibroblasts (A) and myoblasts (B) treated with 10 µM of ASO 1 for 24 h using
the delivery methods indicated above each panel. Cell viability of (C) fibroblasts and (D) myoblasts
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treated with PMO complexed with indicated reagent, uncomplexed and untreated. RT-PCR products
of the ITGA4 transcript amplified from (E) fibroblasts and (F) myoblasts treated as in (A) and (B)
respectively. Shown are the average percentages of exon skipping from three biological replicates
represented as a bar graph below the gel image. GTC: Gene Tools Control PMO. Error bar; SEM.
2.2. Nucleofection Programs for PMO Delivery into Different Cell Lines
Nucleofection is one of the commonly used methods to efficiently deliver nucleic acids, including
PMOs, into cultured cells. Nucleofection is our preferred method for PMO delivery as the test
compounds can be delivered into a million cells (using the 4D-Nucleofector X Kit S) without
compromising the efficiency (Figure 2A) or using excessive amounts of PMO, as well as being
highly reproducible (Figure 2A). We have optimised nucleofection programs using the P3 kit (Table 1)
for multiple, extensively used cell lines that are commercially available, and achieved 70% or more
exon skipping of the target transcript with less than 10% cell death as shown in Figure 2B. We selected
two PMOs, ASO 2 targeting exon 3 of the ITGA4 transcript (Figure 2A), and ASO 3 targeting exon 7 of
the murine Smn transcript [31] for standardised evaluation (Figure 2B). Although ASO 3 was designed
to target the murine Smn transcript, it is also capable of inducing exon 7 skipping from the human
SMN transcript despite 2 mismatches at the 8th and 21st position. From these experiments, it can be
seen that nucleofection is an efficient and reproducible method of transfection.
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Figure 2. (A) RT-PCR ts of ITGA4 transcript amplified from human fibroblasts nucleofected
with ASO 2 at 50 µ c tration in the cuv tte using the P3 nucleofection kit and CA-137 program
and various cell densities. The number of cells nucleofected is shown above the gel. Shown are the
average percentages of exon skipping from three biological replicates represented as a bar graph next
to the gel image. UT: Untreated. Error bar; SEM. (B) RT-PCR products of SMN transcript from Huh7
cells nucleofected with ASO 3 at 50 µM concentration in the cuvette using P3 kit, and CA-137 or Ex-147
program. Shown are the average percentages of exon skipping using CA-137 program from three
biological replicates represented as a bar graph next to the gel image. UT: Untreated. Error bar; SEM.
Table 1. Optimal nucleofection programs for the P3 kit and the cell numbers tested in specified cell lines.
Cell Type Name P3 Program Cell Number
Human dermal fibroblasts HDF CA-137 2.5−10 × 105
Human skeletal muscle myoblasts HSkM CM-138 2.5 × 105
Human T lymphocytes Jurkat CL-120 2-5 × 105
Human Glial (Oligodendrocytic)
Hybrid Cell Line MO3.13
CA-138 2.5 × 105
DR-114 2.5 × 105
EM-110 2.5 × 105
Human neuroblastoma SH-SY5Y CA-137 2.5−10 × 105
Human hepatocarcinoma Huh7 CA-137 2.5 × 105
Human hepatocarcinoma HepG2 EH-100 2. × 105
Murine primary splenocytes DN-100 10 × 105
Murine myoblast H2Kmdx CM-138 2.5 × 105
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3. Discussion
It is often stated that there are three great challenges to genetic therapies: delivery, delivery and
delivery. While the design of the therapeutic vector, plasmid or antisense oligomer is a fundamentally
crucial aspect, without efficient and effective delivery to the target tissue or cells, the most therapeutically
active compound may appear inert. We have extensive experience in designing and assessing the
potential of splice modulating antisense oligomers, initially as research-grade 2′-OMe phosphorothioate
oligonucleotides that can be readily synthesised in-house, and perhaps more importantly, easily and
efficiently transfected into cultured cells as cationic lipoplexes.
Apart from the considerable cost, PMOs have other limitations, including poor cellular/nuclear
uptake unless particular strategies are employed. Indeed, PMOs were discounted as possible splice
switching agents for dystrophin exon skipping after researchers compared PMOs, 2′-OMe, LNA
and peptide nucleic acids (PNA) [16]. The PNA was ineffective while the PMOs induced only
weak exon skipping compared to the 2′-OMe ASOs and LNAs. It is of interest to note that the
transfection conditions to compare these different oligonucleotides were not equivalent in this study,
with polyethylenimine complexed with the 2′-OMe and LNA oligomers, ethoxylated polyethylenimine
mixed with PMO and a DNA sense strand, and no transfection agent for the PNA. We had earlier
shown that an optimised PMO, when annealed to a variety of sense strand DNA/RNA-like leashes
and complexed with Lipofectin™, was found to induce robust exon skipping after transfection at
concentrations as low as 30 nM, whereas the uncomplexed PMO showed no activity at 30-fold higher
transfection concentrations [20].
Conscious of the importance of PMO delivery, we evaluated various protocols to introduce
PMOs into cultured cells. The most common cell types studied in our laboratory are human dermal
fibroblasts and myoblasts, as these cells could be readily obtained from individuals after Human Ethics
Committee approval and informed consent through our collaborating clinicians. Depending upon
commercial availability and tissue-specific gene expression, other cell lines may also be studied, and
we provide nucleofection programs for the P3 kit to deliver PMO into various cell lines, in addition to
liposome transfection.
Convention dictates that when delivering uncharged PMOs into cells with cationic liposome
transfection reagents, annealing the PMO to a complementary strand DNA or RNA-like “leash” would
provide the necessary negative charge for PMO: lipoplex formation. Counter-intuitively, we found
that a leash was not necessary for PMO: lipoplex formation with either Lipofectamine 3000™/2000™
or Lipofectin™. Significantly, these reagents can deliver PMOs into cells with efficiencies similar to
that achieved by nucleofection. Transfection with ASO 1 showed consistent but modest levels of exon
skipping and was therefore chosen for study so it would be possible to discern between the efficiencies
of different delivery protocols confidently [31]. When assessing a PMO that induces efficient skipping
(>80%), it can become more difficult to reliably discern subtle differences in transfection efficiency and
densitometric analysis with titration experiments. Uncomplexed ASO 1 was not taken up by fibroblasts
after 24 h incubation, and therefore, any exon skipping detected in the fibroblasts transfected with
ASO 1 complexed with transfection reagent must be attributed to enhanced delivery through these
transfection reagents. In our experience, Lipofectamine 3000™ is versatile and shows little or no toxicity
in most cell types. It is possible that the cell death observed in fibroblasts treated with Lipofectin™
may be limited by lowering the concentration of Lipofectin™ utilised for PMO delivery. However, the
10 µL/mL Lipofectin™ we applied is lower than the recommended DNA: transfection reagent ratio of
1:1. Lipofectamine 2000™ consistently outperformed Lipofectamine 3000™ in myoblasts regarding
the exon skipping efficiency, although it caused higher levels of cell death. Among the biological
replicates performed in myoblasts, we noticed that there was a positive correlation between the extent
of myotube formation and uncomplexed PMO uptake. However, once the PMO was complexed with a
delivery agent, uptake improved in all cultures, regardless of myotube formation.
The fibroblasts treated with Endo-Porter and PMOs showed anomalies around the cell membrane,
and this may be due to the novel peptide promoting endocytosis and thus stressing the membrane.
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Although endocytosis is a natural biological process in most cells, we speculate that Endo-Porter may
induce a degree of endocytosis that exceeds the capacity of the pathway during normal endogenous
function, compromising the cell membrane and thus inducing cell stress. Analysis of cell stress-related
protein levels in Endo-Porter-treated cells suggested that cells may be under considerable stress, as
indicated by the reduced expression of Cited 2, one of the proteins downregulated under ER stress [32].
Although the level of p21 in Endo-Porter-treated fibroblasts was lower than that in untreated fibroblasts,
we speculate that the untreated fibroblasts were more confluent at collection than the Endo-Porter
treated fibroblasts, accounting for the relatively higher p21 level.
In summary, this study provides various PMOs to modify the expression of broadly expressed
genes that may be used as positive treatments for assessment of PMO delivery in a range of cultured
cell types. We recommend the use of an electroporation system, particularly nucleofection that, over
the years, has provided efficient and reproducible PMO delivery into many different cell types in our
laboratory, with very little evidence of stress on the cells. We have provided optimised programs
for various cell lines using a single P3 kit, but if this system is not available, Lipofectamine 3000™
can be used for reliably delivering PMO to most cell types, including fibroblasts, and Lipofectamine
2000™ for myoblasts. The PMOs described here target genes widely expressed in many different
cell types and could be used as controls to monitor and confirm efficient delivery into most cell lines
under investigation.
4. Materials and Methods
4.1. PMO Nomenclature
The nomenclature of all PMOs outlined in this study is as described by Mann et al. 2002 [33], as it
indicates annealing coordinates and allows a sharp distinction between overlapping ASOs targeting a
common region. Briefly, the first letter designates the species (H: human) followed by the targeted exon
number with the specification of an acceptor (A) or donor (D) site and the annealing coordinates in
brackets from 5′ to 3′ position of the mRNA transcript. The intronic bases are represented by negative
(−) and the exonic position by positive (+). The annealing coordinates were based on the reference
transcript as denoted by NCBI and Ensembl genome browser 96.
4.2. PMOs
The PMOs used in this study, optimised after microwalking and designed to redirect ITGA4 or
Smn pre-mRNA processing [30,31] (Table 2), were purchased from Gene Tools, LLC (Philomath, OR,
USA). These oligomers target ubiquitously expressed genes (ITGA4 and Smn) and may be useful as
positive transfection controls in other studies. These gene targets were chosen as they are widely
expressed throughout common commercial cell lines. Expression patterns of both genes (adapted from
GeneCards.org) can be found in Supplementary Figure S1.
Table 2. Information for ASOs.
Name ASO Nomenclature Sequence (5′ to 3′) Target Protein
ASO 1 ITGA4 H3A (+ 30 + 49) TCTCTCTCTTCCAAACAAGT Integrin alpha 4
ASO 2 ITGA4 H3A (+ 41 + 65) CCCCAACCACTGATTGTCTCTCTCT Integrin alpha 4
ASO 3 Smn M7A (+ 7 + 36) TGAGCACTTTCCTTCTTTTTTATTTTGTCT Survival motor neuron
GTC GTC-Gene Tools Control CCTCTTACCTCAGTTACAATTTATA Beta-globin chain
4.3. Cell Culture
All cell culture reagents were purchased from Thermo Fisher Scientific Australia Pty. Ltd.
(Scoresby, VIC, Australia) and cultures were maintained at 37 ◦C under a 5% CO2/95% air atmosphere,
unless otherwise stated. The use of human cells was approved by the Murdoch University Human
Research Ethics Committee (approval 2013/156). Human dermal fibroblasts were propagated in DMEM
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supplemented with L-Glutamine and 10% foetal bovine serum (FBS). Human myogenic cells were
prepared from biopsies taken from healthy individuals undergoing elective surgery at Royal Perth
Hospital, Perth Western Australia, as described by Rando and Blau [34] with minor modifications [35].
Primary human myogenic cells were propagated in Hams F-10 Medium supplemented with 20%
FBS and 0.5% chick embryo extract (Jomar Life Research, Scoresby, VIC, Australia) on flasks coated
with 100 µg/mL Matrigel (BD Biosciences, Sydney, NSW, Australia). Jurkat cells were supplied by
the European Collection of Cell Cultures (ECACC; Salisbury UK) and purchased from CellBank
Australia (Westmead, NSW, Australia) and maintained in RPMI-1640 supplemented with 10% FBS.
Human glial (oligodendrocytic) hybrid cell line MO3.13 was purchased from BioScientific Pty. Ltd.
(Kirrawee, NSW, Australia) and maintained in DMEM supplemented with 10% FBS. The human bone
marrow neuroblastoma cell line, SH-SY5Y, was purchased from ATCC (In Vitro Technologies Pty.
Ltd., Noble Park North, VIC, Australia) and maintained in a 1:1 mixture of MEM and F-12 Medium
supplemented with 10% FBS. The human hepatocarcinoma cell lines, Huh7 and HepG2, were supplied
by the JCRB Cell Bank (Osaka, Japan) and purchased from CellBank Australia (Westmead, NSW,
Australia). These cells were maintained in DMEM supplemented with 10% FBS. Murine H2k mdx
myoblasts were cultured in poly D-lysine (50 µg/mL) and Matrigel (100 µg/mL) coated flasks at 33 ◦C
under a 10% CO2/90% air atmosphere in high-glucose DMEM supplemented with 20% FBS and 10%
horse serum, 0.5% chicken embryo extract and 20 units/mL γ-interferon (Roche Products Pty. Ltd.,
Sydney, NSW, Australia).
4.4. Isolation of Splenocytes
Splenocytes were freshly isolated from the spleens taken from two mdx mice (Murdoch University
approval number R2829/16). All steps were performed on ice and in RPMI-1640 supplemented with 10%
FBS. Both spleens were sliced into small pieces (approximately 4 mm2) and mashed using the frosted
side of pre-sterilised glass slide. The undissociated pieces of spleen were removed by centrifugation at
100× g for 8 min before the supernatant was centrifuged for a further 8 min at 200× g. The pellet of
splenocytes was resuspended in 10% FBS, RPMI-1640 and the number of cells was determined using a
haemocytometer (Sigma-Aldrich, Sydney, NSW, Australia).
4.5. Transfection
Approximately 70% confluency/15,000 fibroblasts per well were plated in a 24-well plate one day
prior to transfection [31]. Human myoblasts were plated in a 24-well plate that had been previously
coated for 1 h with 50 µg/mL poly D-lysine (Sigma-Aldrich, Sydney, NSW, Australia) and 100 µg/mL
Matrigel at 70% confluency/30,000 cells per well in Low Glucose DMEM supplemented with 5%
horse serum, and cultured for 24 h [36]. Transfection complexes were formed according to the
manufacturer’s recommendations. PMO was transfected at a final concentration of 10 µM using
3 µL/mL Lipofectamine 3000™, 10 µL/mL Lipofectin™ or 10 µL/mL Lipofectamine 2000™. Briefly,
the PMO and transfection reagents were separately diluted into 50 µL OptiMEM before mixing.
PMO/lipid complexes were formed by incubating for the recommended time (10–15 min Lipofectamine
3000™; 30–45 min Lipofectin™; 5 min Lipofectamine 2000™) at room temperature before topping up
to 300 µL with OptiMEM and adding to the cells. For Endo-Porter (Gene Tools) transfection, 80%
confluency/25,000 cells were plated per well (as per the manufacturer’s recommendations) one day
before transfection, replaced with fresh media, and PMO was added to the media before adding the
Endo-Porter (3 µL/mL).
4.6. Nucleofection
All nucleofections were performed using the 4D-Nucleofector™ X Unit and P3 kit (Lonza, Mt
Waverley, VIC, Australia) with the concentration of PMO set at 50 µM in the cuvette (volume of
1 µL 1 mM PMO in 20 µL cuvette volume), unless otherwise stated. The cell type, number of cells,
and the program used for nucleofection is shown in Table 1, in accordance with the manufacturer’s
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recommendations. After the nucleofection pulse with the PMO, the cells were allowed to recover for
10 min at room temperature before being resuspended in the appropriate growth medium. Total RNA
was extracted after 24 h using Direct-zol™ RNA Kit (Zymo Research, Tustin, CA, USA) according to
the manufacturer’s instructions.
4.7. Microscopy
The images of transfected cells were captured using a Nikon® TS100 (Nikon, Sydney, NSW,
Australia) prior to extracting total RNA using the Direct-zol™ RNA Kit.
4.8. RT-PCR
RT-PCR was performed using a Superscript III One-Step RT-PCR System (Life Technologies,
(Scoresby, VIC, Australia). Total RNA (50 ng) from PMO-treated and untreated cells was used as a
template for all reactions. RT-PCR amplification across the ITGA4 transcript was performed using
exon 1F (5′ gagagcgcgctgctttaccagg 3′) and 10R (5′ gccatcattgtcaatgtcgcca 3′) primers with the cycling
conditions of 55 ◦C for 30 min for the reverse transcription step, followed by 28 cycles of 94 ◦C for
30 s, 55 ◦C for 30 s and 68 ◦C for 2 min. The RT-PCR products were fractionated on 2% agarose gels in
Tris-acetate EDTA buffer and images of RedSafe™ (iNtRON Biotechnology, Inc., Burlington, MA, USA)
stained gels were captured using a Fusion-FX gel documentation system (Vilber Lourmat, Marne la
Vallée, France). Densitometric analysis was performed using ImageJ (NIH).
4.9. Protein Stress Array
The GTC PMO was delivered to fibroblasts using Endo-Porter as described above and analysis
of stress proteins performed using the proteome profiler human cell stress array kit (R&D Systems,
Minneapolis, MN, USA) according to the manufacturer’s protocol. Protein concentrations were
determined using Pierce BCA protein assay kit (Thermo Fisher Scientific, Scoresby, VIC, Australia) and
200 µg protein was used for each assay. The pixel density was analysed using Image J (NIH).
Supplementary Materials: The following are available online, Figure S1: Genecards.org gene expression profile
of human ITGA4 and SMN2 transcripts in major tissues. Figure S2: Normal human dermal fibroblasts were either
untreated or treated with Endo-Porter complexed with GTC for 48 hours, and 200 µg of cell lysates were analysed
on human stress arrays. Figure S3: Experimental biological replicates for Figure 1.
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